Alert # 1:
Due to unprecedented levels of demand for SHINGRIX, providers should anticipate ordering limits, backorders and shipping delays for SHINGRIX. GSK is currently working to make more doses available in the near term for the US market in order to meet the demand for this vaccine.
Alert # 2:
Due to Merck’s continued hepatitis B supply shortage though the middle of Q2 2019, GSK has communicated to the CDC that we will be able to cover this shortage using a combination of ENGERIX-B, GSK’s monovalent hepatitis B vaccine, and PEDIARIX (DTaP-Hep B-IPV) (for doses other than the birth dose).
